Avandia gets black-box warning

The following isn't a big shock, but it's still an important development--blockbuster diabetes drug Avandia will now carry a black-box warning. In addition to posting the warning on Avandia packaging, GlaxoSmithKline has also agreed to conduct a new Avandia trial, comparing the drug directly with Actos and other related drugs.

GlaxoSmithKline has struggled to maintain Avandia's reputation since a report came out earlier this year suggesting that the drug could be linked to a 43 percent increased risk of heart attacks in patients who took it.  Sales of the drug, once the world's best-selling diabetes medication, have fallen by half since the release of the journal article, after hitting $3.3 billion in 2006.

While the black-box designation is no picnic, Glaxo is actually getting kinder treatment here than it did elsewhere. The Canadian health program will no longer pay for Avandia as a stand-alone therapy, and European regulators are limiting its use to a subset of diabetes patients.

To find out more about Avandia's status:
- read this Chicago Tribune article

ALSO:  Elsewhere on the pharma front, Glaxo is battling FDA attempts to create a third class of drugs which would not require a prescription, but wouldn't be given to consumers until they got counseling from a pharmacist. Release

Related Articles:
Avandia controversy sparks FDA criticism. Report
Glaxo: Avandia's safe as other diabetes drugs. Report
Avandia critic: FDA launched smear campaign. Report
Diabetes expert issued harsh Avandia critique in 2000. Report

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.